Marshall Wace
VC Fund
London, United Kingdom
Marshall Wace is a hedge fund manager specializing in global long/short equity. The firm has investment management offices in London; New York; and Hong Kong. Marshall Wace LLP was named Management Firm of the Year by the EuroHedge Awards 2011, reflecting the strong performance delivered by a number of our funds during the year. The firm isdedicated to the objective of providing its clients with a persistent, risk-adjusted return on their investment. Through a range of products, investors can select funds offering variable sources of alpha and beta, in different combinations, from equity markets around the world.Marshall Wace brings together two distinct but complementary approaches to asset management. First, traditional, fundamental long/short investing grounded in stock-specific analytical research, and secondly, Marshall Wace TOPS (‘MW TOPS’), the pioneering, and proprietary, systematic, alpha capture strategy.
- Total investments:
- 86
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries Marshall Wace invests in
Stages Marshall Wace invests in
Countries Marshall Wace invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amit Rajpal
|
|||
Andrew Goldberg
|
|||
Ian Wace
|
|||
|
Paul Marshall
|
|||
Steven Binetter
|
Investment Focus
Industry
- Biotechnology 33 (38%)
- Health Care 27 (31%)
- Pharmaceutical 14 (16%)
- FinTech 12 (14%)
- Financial Services 12 (14%)
Stage
- Series C 15 (17%)
- Series B 13 (15%)
- Post-IPO Equity 12 (14%)
- Series E 8 (9%)
- Funding Round 6 (7%)
Country
- United States 42 (49%)
- India 5 (6%)
- Switzerland 4 (5%)
- United Kingdom 3 (3%)
- Canada 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Amit Rajpal
CEO & Portfolio Manager
|
CEO & Portfolio Manager | Total investments: 9 | Find email | |
|
Andrew Goldberg
Managing Director
|
Managing Director | Total investments: 5 | Find email | |
|
Ian Wace
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
|
Paul Marshall
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
|
Steven Binetter
Portfolio Manager
|
Portfolio Manager | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Processa Pharmaceuticals
|
Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M / Post-IPO Equity / Jul 29, 2026 | |
Draig Therapeutics
|
Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses. | $65M / Series B / Jul 14, 2026 | |
Circle
|
Circle is a financial technology company that develops and manages digital currencies and blockchain-based financial infrastructure. It issues USD Coin (USDC) and Euro Coin (EURC), both fully backed stablecoins designed for global payments and digital transactions. Circle's platform supports businesses in integrating stablecoins into theiroperations, including cross-border payments and financial applications. Through the Circle Payments Network, it enables real-time settlement for financial institutions using USDC and EURC. | $222M / Post-IPO Equity / May 11, 2026 | |
Ray Therapeutics
|
Ray Therapeutics is a biotech company developing optogenetic gene therapies for patients with blinding diseases. | $125M / Series B / Apr 21, 2026 | |
Achieve Life Science
|
Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M / Post-IPO Equity / Apr 16, 2026 | |
Relmada Therapeutics
|
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor(NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.() | $160M / Post-IPO Equity / Mar 09, 2026 | |
Opus Genetics(formerly Ocuphire Pharma)
|
Ocuphire Pharma is a clinical-stage biopharmaceutical company focuses on the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. It is currently focused on providing a novel once-daily eye drop treatment option, Nyxol, to treat multiple front-of-the-eye disorders, including night visiondisturbances, glaucoma, pharmacologically-induced mydriasis, and presbyopia. Nyxol eye drops are an investigational 505(b)(2) drug candidate in late-stage clinical development with over a decade of safety and efficacy data from Phase 1 and 2 trials. Part of their strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and the back of the eyes and to seek strategic partners for global commercialization.The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. | $25M / Post-IPO Equity / Feb 13, 2026 | |
Third Arc Bio
|
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M / Series A / Feb 04, 2026 | |
ALX Oncology
|
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University.This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1. | $150M / Post-IPO Equity / Jan 30, 2026 | |
Parabilis Medicines
|
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M / Series F / Jan 08, 2026 | |
| See all 86 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Marshall Wace invest in?
Marshall Wace invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series C and Series B stage. Most of the 86 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Marshall Wace?
Public channels for Marshall Wace include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Marshall Wace?
The team at Marshall Wace includes Amit Rajpal (CEO & Portfolio Manager), Andrew Goldberg (Managing Director) and Ian Wace (Co-Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
